Abstract
Replication-competent adenoviruses (Ads) were used for oncolytic virotherapy soon after they were discovered. Recently mutated and genetically engineered Ads have been shown to selectively lyse tumor cells. We have split the human Ad type 5 genome into two defective viruses that complement each other only in certain tumor cells. The genome of one of these vectors, GT5610, contains only the minimal viral elements required in cis for replication and packaging and the E1 viral genes with E1A under the control of the human α-fetoprotein promoter. This “controlled” vector has a capacity for 30 kilobases of foreign DNA. The supplemental vector, AdHβ, contains all adenoviral genes except for E1. Both vectors were designed to carry heterologous reporter genes whose expression could be detected throughout the tumor. Coinfection of hepatocarcinoma cells that have the capacity to transcribe genes under the control of the α-fetoprotein promoter leads to cell lysis and copropagation. The oncolytic spread of these complementary vectors in vivo was demonstrated by the intratumoral injection of human hepatocarcinomas xenografted in severe combined immunodeficient (SCID) mice. This system presents safety and gene capacity features that could yield a therapeutic advantage over oncolysis by a single virus.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Alemany, R., Lai, S., Lou, Y. et al. Complementary adenoviral vectors for oncolysis. Cancer Gene Ther 6, 21–25 (1999). https://doi.org/10.1038/sj.cgt.7700001
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700001
Keywords
This article is cited by
-
Semireplication-competent vesicular stomatitis virus as a novel platform for oncolytic virotherapy
Journal of Molecular Medicine (2012)
-
Analysis of adenovirus trans-complementation-mediated gene expression controlled by melanoma-specific TETP promoter in vitro
Virology Journal (2010)
-
E1A, E1B double-restricted replicative adenovirus at low dose greatly augments tumor-specific suicide gene therapy for gallbladder cancer
Cancer Gene Therapy (2009)
-
Anticancer activity of oncolytic adenovirus vector armed with IFN-α and ADP is enhanced by pharmacologically controlled expression of TRAIL
Cancer Gene Therapy (2008)
-
Evaluation of Twenty-One Human Adenovirus Types and One Infectivity-Enhanced Adenovirus for the Treatment of Malignant Melanoma
Journal of Investigative Dermatology (2008)